Live Terminal

Artisan Partners calls for Novartis board changes amid trial, acquisition failures

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: Artisan Partners calls for Novartis board changes amid trial, acquisition failures
📊
Market & Financial Impact: Live financial intelligence and market filing report on ZeroLive.
💡
Actionable Insight: Monitor price volume action at market open; check key technical support/resistance levels.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Investing.com -- A major shareholder in Novartis has demanded changes to the Swiss drugmaker's board to improve corporate governance following a sharp decline in shares this week after two consecutive trial setbacks.

David Samra, managing director at Artisan Partners and founding partner of International Value Group, told Reuters Thursday that multiple past chairmen had failed Novartis on acquisitions and that the company needs to reform its deal oversight process.

"The party is over," Samra said, urging Novartis Chairman Giovanni Caforio to take action. Asset manager Artisan ranks among Novartis' 20 largest shareholders.

"I think he needs to make changes at the board level. One of them should be on improving the team that's doing these deals because clearly they have been uninspiring at best," Samra said.

📰
Official Publisher Attribution: This report is aggregated from Yahoo Finance. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on Yahoo Finance ↗
Link copied to clipboard! ✅